# Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

> **NCT06431919** · NA · RECRUITING · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 260 (estimated)

## Conditions studied

- Decompensated Cirrhosis
- Cirrhotic Cardiomyopathy
- Cirrhosis, Liver
- Left Ventricular Diastolic Dysfunction
- Acute Kidney Injury

## Interventions

- **DRUG:** Simvastatin 20mg
- **DRUG:** Carvedilol 3.125 mg

## Key facts

- **NCT ID:** NCT06431919
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-02
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06431919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06431919, "Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06431919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*